Biora Therapeutics Company Insiders
| BIOR Stock | USD 1.93 0.14 7.82% |
Biora Therapeutics employs about 58 people. The company is managed by 12 executives with a total tenure of roughly 136 years, averaging almost 11.0 years of service per executive, having 4.83 employees per reported executive. Discussion of Biora Therapeutics' management performance can provide insight into the enterprise performance.
Biora |
Biora Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.2506) % which means that it has lost $1.2506 on every $100 spent on assets. This is way below average. Biora Therapeutics' management efficiency ratios could be used to measure how well Biora Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Biora Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 11/28/2024, Return On Equity is likely to grow to 1.99, though Return On Tangible Assets are likely to grow to (4.69). At this time, Biora Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 11/28/2024, Intangible Assets is likely to grow to about 3.8 M, while Net Tangible Assets are likely to drop (86 M).As of 11/28/2024, Common Stock Shares Outstanding is likely to grow to about 16.6 M, while Net Loss is likely to drop (233.8 M).
Biora Therapeutics Workforce Comparison
Biora Therapeutics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 188. Biora Therapeutics totals roughly 58.0 in number of employees claiming about 31% of equities under Health Care industry.
Biora Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biora Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biora Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biora Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biora Therapeutics Notable Stakeholders
A Biora Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biora Therapeutics often face trade-offs trying to please all of them. Biora Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biora Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Clarke JD | General VP | Profile | |
| Eric Fox | VP Treasurer | Profile | |
| Aditya MBA | CEO Director | Profile | |
| Kevin Howe | Senior Operations | Profile | |
| Sharat Singh | Head Research | Profile | |
| Robyn Hatton | Head Resources | Profile | |
| Paul MBA | Head Operations | Profile | |
| Eric dEsparbes | Chief Officer | Profile | |
| George Gianakopoulos | Senior Sales | Profile | |
| Ariella MD | Chief Officer | Profile | |
| Troy Seelye | Chief Officer | Profile | |
| James MBA | Head Development | Profile |
About Biora Therapeutics Management Performance
The success or failure of an entity such as Biora Therapeutics often depends on how effective the management is. Biora Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biora management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biora management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.94) | (4.69) | |
| Return On Capital Employed | 2.11 | 2.22 | |
| Return On Assets | (3.98) | (3.78) | |
| Return On Equity | 1.22 | 1.99 |
Biora Therapeutics Workforce Analysis
Traditionally, organizations such as Biora Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biora Therapeutics within its industry.Biora Therapeutics Manpower Efficiency
Return on Biora Therapeutics Manpower
| Revenue Per Employee | 68.97 | |
| Revenue Per Executive | 333 | |
| Net Loss Per Employee | 2.1M | |
| Net Loss Per Executive | 10.3M |
Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.